Generex Biotechnology Announces Publication of Novel Immunotherapeutic Cancer Vaccine...

Generex Biotechnology Announces Publication of Novel Immunotherapeutic Cancer
Vaccine Studies

WORCESTER, Mass., Jan. 12, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology
Corporation (Nasdaq:GNBT) (www.generex.com) announced today the publication of a
report reviewing the studies performed to date with the immunotherapeutic agent
AE37, which is being developed by the Company's wholly-owned immunotherapeutics
subsidiary Antigen Express, Inc. (www.antigenexpress.com). The compound is
currently the subject of a Phase II clinical trial in patients with breast
cancer, a Phase I clinical trial in prostate cancer patients, and another Phase
I clinical trial wherein the compound will be combined with another vaccine
peptide in patients with either ovarian or breast cancer.

The report, entitled "CD4+ T cells in antitumor immunity: utility of an Ii-Key
HER2/neu hybrid peptide vaccine (AE37)", appeared in the January 2009 issue of
Expert Opinion on Biological Therapy (Vol. 9, No. 1, Pages 71-78) and is
co-authored by Dr. Eric von Hofe, President of Antigen Express. The study
reviews the clinical as well as the pre-clinical data on AE37, comparing it with
other vaccines that have been investigated in the clinic. In addition to being
shown to be safe and well tolerated in clinical studies, the report concludes
that AE37 has superior immunogenicity to other peptide vaccines investigated to
date. In addition, the value of specific CD4+ T cell stimulation is also
underscored.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug
delivery systems and technologies. Generex has developed a proprietary platform
technology for the delivery of drugs into the human body through the oral cavity
(with no deposit in the lungs). The Company's proprietary liquid formulations
allow drugs typically administered by injection to be absorbed into the body by
the lining of the inner mouth using the Company's proprietary RapidMist device.
The Company's flagship product, oral insulin (Generex Oral-lyn), which is
available for sale in India and Ecuador for the treatment of subjects with
Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites
around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex.
The core platform technologies of Antigen Express comprise immunotherapeutics
for the treatment of malignant, infectious, allergic, and autoimmune diseases.
For more information, visit the Generex website at www.generex.com or the
Antigen Express website at www.antigenexpress.com.

The Generex Biotechnology Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex
representatives in respect of the same subject matter may contain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by
introductory words such as "expects," "plans," "intends," "believes," "will,"
"estimates," "forecasts," "projects," or words of similar meaning, and by the
fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing potential product
applications, potential collaborations, product development activities, clinical
studies, regulatory submissions and approvals, and similar operating matters.
Many factors may cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and uncertainties,
some of which are known and others of which are not. Known risks and
uncertainties include those identified from time to time in the reports filed by
Generex with the Securities and Exchange Commission, which should be considered
together with any forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing undue
reliance on such statements. Generex undertakes no obligation to update publicly
any forward-looking statements, whether as a result of new information, future
events or otherwise. Generex cannot be sure when or if it will be permitted by
regulatory agencies to undertake additional clinical trials or to commence any
particular phase of clinical trials. Because of this, statements regarding the
expected timing of clinical trials cannot be regarded as actual predictions of
when Generex will obtain regulatory approval for any "phase" of clinical trials.
Generex claims the protection of the safe harbor for forward-looking statements
that is contained in the Private Securities Litigation Reform Act.

-0-
CONTACT: CEOcast, Inc.
Gary Nash
212-732-4300

American Capital Ventures, Inc.
Howard Gostfrand
1-877-918-0774